Lundbeck has secured orphan designation from the European Commission for asedebart, its investigational anti‑ACTH monoclonal ...
FairJourney Bio has published a peer‑reviewed study in mAbs describing a novel antibody‑engineering approach designed to ...
AC Immune has announced encouraging preliminary findings from its phase 1 first‑in‑human study of ACI‑19764, an orally ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for the rapid ...
Teva Pharmaceuticals has announced that the US Food and Drug Administration has accepted the new drug application for ...
The MHRA’s position is that MBMPs fall within the scope of the existing UK medicines regulatory framework set out in the ...
HUTCHMED has reported positive high‑level results from the Saffron phase 3 trial evaluating Orpathys (savolitinib) plus ...
Unlike antibody drug conjugates, KJ‑103 does not contain a cytotoxic payload. It recruits immune cells to kill tumour cells ...
ALK has announced that the Scottish Medicines Consortium (SMC) has accepted ACARIZAX (12 SQ-HDM SLIT) for adults diagnosed ...
VarmX has enrolled the first participant in its global phase 3 EquilibriX S trial evaluating VMX C001 for restoring normal coagulation in patients taking FXa inhibitors who require an urgent surgery ...
Androlabs has appointed EffRx Pharmaceuticals as its commercial partner in Switzerland for Testavan, a testosterone ...
Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to accelerate drug discovery and modernise its global operations through agentic AI and cloud technologies. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results